ClinicalTrials.gg
Enrolling by invitationNCT06716944SAMUpdated Dec 4, 2024

Self-acupuncture for Migraines Feasibility Study

A Phase 1/2 interventional study of Acupuncture in Migraine, sponsored by University of West London. Enrolling by invitation at 1 site in United Kingdom. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2024-12-04.

Sponsored by University of West London · Phase 1/2, Interventional, and Treatment

How we know

From the registry’s dates

  • Primary completion was expected by Sep 2025, 1 year 2 months ago, but the record still lists the study as enrolling by invitation.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1/2
Study type
Interventional
Enrollment
60
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 80 studies in Migraine Disorders with a site in United Kingdom — 11 open to participants now, 18 under way, 13 of them phase 3. Migraine Disorders · United Kingdom.

Planned enrollment
57th of 70
60 · median 466
Started
2024
with 3 others
Phase 1/2
Only one
of the 80
Primary completion
2025-09
later than 2 of 17 live
Registered
74th of 80
by date

Among the 80 studies in Migraine Disorders with a site in United Kingdom, this one is the 57th largest by planned enrollment of the 70 interventional ones that give a count, is one of 4 that started in 2024, is the only one in phase 1/2, reaches primary completion later than 2 of the 17 other live ones, and was the 74th registered.

Migraine Disorders

1,659 studies on the registry are indexed under Migraine Disorders; 340 are open to participants now.

Browse Migraine Disorders studies →

Open to participants now

11 of the 80 studies in Migraine Disorders with a site in United Kingdom are open now. Recruiting first, the newest first:

5 more — sign in →

All 11 open studies →

A study can be open while its sites in United Kingdom have not opened yet or have stopped. Only those recruiting at a site in United Kingdom →

Who these studies take

Of the 217 Migraine Disorders studies recruiting now, 66 (30%) set no upper age limit and 136 (63%) stop at 75 or younger; 44 take children under 18; 37 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 80 studies in Migraine Disorders with a site in United Kingdom, or all of them as a file.
02

Study summary

Patients who have had a course of acupuncture at the Royal London Hospital for Integrated Medicine to manage their migraines, and found it effective, will be taught to do self-acupuncture. This is a feasibility study so the main aim is to test the trial design but the researchers will also explore self-acupuncture's effectiveness, acceptability and safety.

Read the detailed description

Aim: The proposed study will evaluate the feasibility of teaching SA to patients with migraines in the United Kingdom National Health Service setting.

Methodology: The study will employ a pragmatic, mixed-methods, randomised, parallel-group, exploratory design. The study will compare SA plus standard care versus standard care alone. Participants will complete outcome measures at various time points and be invited to take part in a qualitative telephone interview to explore their views on the design of the study and acceptability of the intervention. The researcher will take field notes of the observation of the SA teaching session to explore the acceptability of the SA teaching method. Data will be analysed to test the hypothesis.

03

Conditions studied

  • Migraine

Browse trials for

Keywords

  • migraine
  • acupuncture
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Adult patients aged 18 years old and over.
  • Patients with migraines (when topiramate and propranolol are unsuitable).
  • Patients who have been referred to the Royal London Hospital for Integrated Medicine (RLHIM) for a course of at least 6 acupuncture sessions to manage their migraines.
  • Patients who have completed a course of acupuncture for the management of their migraines at RLHIM and self-declare that they benefitted from it.
  • Patients must have completed the course of acupuncture within the last 3 to 24 months.

Exclusion criteria

Exclusion Criteria:

  • Patients unwilling to participate (for instance due to needle phobia).
  • Patients currently receiving acupuncture.
  • Patients with severe clotting dysfunction or who bruise spontaneously.
  • Patients unable to complete the questionnaires as judged by the researchers.
  • Patients who have previously been taught or have practiced SA.
  • Patients who are assessed as being unable to do SA (such as if they have poor hand function).
05

Study design

Phase
Phase 1 / Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
60 participants (estimated)

Study arms

  • Active comparator
    self-acupuncture plus usual care

    Participants will be taught to do self-acupuncture to manage their migraines. They can also do all the other things they normally do to manage their migraines apart from having acupuncture elsewhere.

    Device: Acupuncture

  • No intervention
    usual care

    Participants can do all the other things they normally do to manage their migraines apart from having acupuncture elsewhere.

Interventions

  • DeviceAcupuncture

    self-acupuncture

06

What researchers measure

Primary outcomes

  1. Headache Impact Test (HIT6)

    HIT-6 assesses the burden of headaches (including migraine) by assessing the impact of headaches on peoples' daily living, work and social situations. Patients rate six areas of potential impact on a 5-part scale from 'never' to 'always'.

    Time frame: From enrolment to end of intervention at 24 weeks

Other outcomes

  1. Migraine Disability Assessment (MIDAS)

    MIDAS assesses the impact headaches or migraines have on peoples' daily living. Patients record the number of days in the last three months that their migraine has impacted their work, household work and social activities (there are five items in the measure).

    Time frame: From enrolment to end of intervention at 24 weeks

  2. Migraine-Specific Quality of Life Questionnaire (MSQ v2.1)

    MSQ v2.1 assesses the impact of migraine on peoples' quality of life. Patients rate how often in the last four weeks their migraine has impacted various areas of daily living. The questionnaire consists of 14 questions which relate to three areas: daily activities the patient was restricted from doing, daily activities the patient was prevented from doing and impact on emotional wellbeing. Patients can rate the impact of each item on a 6-part scale from 'none of the time' to 'all of the time'.

    Time frame: From enrolment to end of intervention at 24 weeks

  3. Pain Catastrophising Scale (PCS)

    The PCS measures the impact of pain on peoples' daily living. The questionnaire consists of 13 items. Patients rate the impact pain has on these items on a 5-part scale from 'not at all' to 'all of the time'.

    Time frame: From enrolment to end of intervention at 24 weeks

  4. Migraine diary

    Participants will be asked to keep a diary of their migraines. They will be asked to record the frequency, duration and severity of their migraines, other symptoms they experienced (such as dizziness or nausea), any migraine or pain medication they took and any other comments.

    Time frame: From enrolment to end of intervention at 24 weeks

07

Study locations

1 site
08

References and documents

Individual participant data

Plan to share: Undecided — I'm not sure what it involves

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Started Sep 2024 (actual). Primary completion is estimated for Sep 2025, 12 months after the start.

How these figures are worked out, and which studies are left out of them.

Registered
Oct 29, 2024
First posted
Dec 4, 2024
StartActual
Sep 13, 2024
Primary completionEst.
Sep 2025
CompletionEst.
Mar 2026
Last update
Dec 4, 2024
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Dec 4, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06716944
Lead sponsor
University of West London
Responsible party
Catrina Davy (Chief investigator, University of West London) — Principal investigator
First posted
Dec 4, 2024
Start date
Sep 13, 2024
Primary completion
Sep 2025 (estimated)
Completion
Mar 2026 (estimated)
Last update
Dec 4, 2024

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

No contact was published for this record. The registry link below has the sponsor’s details.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion